scientific committee: local organization - … scientific committee: prof. dr. eric raymond prof....

1

Scientific committee: Prof. Dr. Eric Raymond Prof. Dr. Christian Rolfo Prof. Dr. Frits Peters P. D. Annette Larsen P. D. Elisa Giovannetti P. D. Marc Peeters Local organization: Responsible: Dr. Marleen Roels Dr. Marco Giallombardo Dr. Pablo Reclusa

Prof. Dr. Eric Raymond Prof. Dr. Christian Rolfo Hospital Beaujon Paris (FR) Antwerp Univ. (BE) PAMM chair Local chair

2

Golden sponsor

Silver sponsors

Bronze sponsors

3

Table of content

Table of content

1) EORTC PAMM Secretariat 4

2) EORTC PAMM Steering Committee 4

3) Young Oncologists/Scientists: 4

4) EORTC-PAMM fellowships grant award winners 4

5) Introduction 5

6) Program 6

7) Overview abstracts speakers 14

8) Overview oral presentations 17

4

1) EORTC secretariat

Chair: E. Raymond (FR)

Secretary: G. Peters (NL)

Treasurer: Annette Larsen

2) EORTC-PAMM Steering Committee

E. Chatelut, Toulouse (FR)

M. Hegi, Lausanne (CH)

G. Hempel, Muenster (DE)

B. Leyland-Jones, Montreal (CA)

R. Phillips, Bradford (GB)

J. Robert, Bordeaux (FR)

A. Skladanowsky, Gdansk (PL)

N. Zaffaroni, Milan (IT)

3) Young Oncologists/Scientists:

S. Faivre, Paris (FR)

E. Giovannetti (NL)

A. Westwell, Cardiff (GB)

4) EORTC-PAMM fellowship grant award winners

Marcin Serocki

Laura Meijer

Tessa Lelarge

Martina Liebich

5

3) Introduction

Dear colleagues,

It is my pleasure to welcome you to Antwerp, heart of the Flemish region, a vibrant city full of

history, taste and an economical motor of Belgium. Antwerp is also the house of our University, one

of the major Belgian universities and the Antwerp University Hospital. The University of Antwerp has

approximately 20 000 students and is still growing, which makes it the third largest university in

Flanders, with more than 200 academic programs, including those only in English. The University

Hospital of Antwerp is a center with 38 high-level medical departments, with 573 beds, and a high

clinical research activity.

This year Antwerp is proud to host the 37th EORTC PAMM Winter meeting, an important

multidisciplinary event. The theme for this edition is “Improving translational Research: from the lab

to clinical practice” and we want to reflect that in the scientific program. The agenda includes

multidisciplinary topics with a big participation of young and senior investigators, prioritizing the

scientific discussion and the contribution from all the participants. Our aim is to create and to

consolidate the networking between different researchers with a very busy interesting program.

We hope you enjoy the meeting and our city.

Welcome!

Prof. Dr. Christian Rolfo

Local Chair

6

4) EORTC-PAMM 2016 – Program

Tuesday , February 9th

18.30 Drug Discovery Committee

19:45 PAMM Committee meeting

Wednesday February 10th

7.30 - 8.00 am: Registration & welcome coffee

8.15: Open Ceremony: Chairs Welcome: Eric Raymond (PAMM Chair) - Christian Rolfo (Local Chair)

8.30: Minisymposium “Multidisciplinary approaches for druggable targets in key signalling pathways

(part I): PI3KA/Akt and BRAF/Mek signaling”

Chairs: Jacques De Greve (Brussels, BE)

08:30 - 08:50 Point of view of the Molecular Biologist Andrea Cavazzoni (Parma, IT)

08:50 - 09:10 Point of view of the Pharmacologist Paola Perego (Milano, IT)

09:10 - 09:30 Point of view of the Oncologist Marc Peeters (Antwerp, BE)

09:30 - 09:40 Panel discussion

09:40 - 10:25 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#9 Overcoming intrinsic cetuximab resistance an in vitro study on the potential of afatinib in HNSCC and CRC cell lines. Ines De Pauw (Antwerp, BE) Abstract#25 ERBB pathway inhibition synergizes with MEK and AKT antagonists in organoid models of pancreatic cancer. Mariano Ponz Sarvise (Cold Spring, NY, US)

10.30: Coffee break and poster session

7

11.00: Minisymposium “Multidisciplinary approaches for druggable targets in key signalling pathways (part II): EGFR, ALK, and MET Chairs: Annette Larsen

11:00 - 11:20 EGFR, ALK, and MET inhibitors in cancer treatment C. Santarpia (Messina, IT)

11:20 - 11:40 First Line Treatment Eric Raymond (Paris, FR)

11:40 - 12:00 Treatment after resistance Christian Rolfo (Antwerp, BE)


12:10 - 12:55 Young investigators - 3 abstracts presentation: 3x10 = 30’ (and 5’ discussion : 2 questions) Abstract#32 The cMET pathway in non-small cell lung cancer: in search for aberrations. Nele van der Steen (Antwerp, BE) Abstract#3 Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Leticia G. Leon (Tenerife, Spain) Abstract#20 APR-246 strongly synergizes with olaparib through various

pathways in non-small cell lung cancer. Christophe Deben (Antwerp, BE)

13.00: Lunch and networking 14.00: MicroRNA: challenges in the new molecular era Chairs: Nadia Zaffaroni (Milano, IT)

14:00 - 14:20 MicroRNA: real situation and opportunities Raffaele Calogero (Torino, IT)

14:20 - 14:40 Preclinical and clinical data on miRNA: mRNA regulatory network Mireia Mato Prado (London, UK)

14:40 - 15:00 MicroRNA as a druggable target Marco Rossi (Catanzaro, IT)


15:10 - 15:25 Young investigators - 1 abstract presentation: 1x10 = 10’ (and 5’ discussion : 2 questions) Abstract#24 The prognostic significance of miR-21 in radically resected cholangiocarcinomas. Ingrid Garajova (Bologna, IT)

15.30: Coffee break and poster visit

8

16.00: The omics revolution & company

Chairs: R. Phillips, Bradford (GB)

16:00 - 16:20 Proteomics Evelyne Maes (BE)

16:20 - 16:40 Translating cancer genomics to precision medicine Ruth Porta (ES


16:50 - 17:35 Young investigators - 3 abstracts presentation: 3x10 = 30’ (and 5’ discussion : 2 questions) Abstract#14 Variations in copy number in the malignant pleural

mesothelioma genome Marieke Hylebos (Antwerp, BE)

Abstracts#15 A phosphoproteomic analysis of pancreatic cancer for therapy

response prediction. Tessa Le Large (Amsterdam, NL)

Abstract#38 Role of Genetic Polymorphisms on Response to R-CHOP

regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a

Multicenter Prospective Pharmacogenetic Study. G. Perrone (Firenze, IT)

17.35: News from the Lab: CRISPR “The disruptor” and other news in lab: Chairs: Filip Lardon (BE)

17:35 - 17:50 Biological rationale Joseph Arturo Pinto Oblitas(Lima, PE)

17:50 - 18:05 Basic research application and opportunities Elias Adriaenssens (Antwerp, BE)

18:05 - 18:25 Role of aberrant alternative splicing in drug resistance Jacqueline Cloos (NL)


18:35 - 19:10 Young investigators - 3 abstracts presentation: = 10’ (and 5’ discussion : 2 questions) Abstract# 12 Spliceosome inhibition as novel strategy against diffuse

malignant peritoneal mesothelioma Rocco Sciarrillo (Amsterdam, NL)

Abstract#21 Synthesis and biological evaluation of novel functionalized

analogues of batracylin with synthetic aminoacids an unexpected effect on

centromere segregation in tumor cells through a dual inhibition of

topoisomerase II and Aurora B. Marcin Serocki (Gdansk, PL)

Abstract#34 The use of a new whole slide imaging platform to set up an

international multi-center validation study on the assessment of the

histological growth pattern of liver metastases. W. Waelput (Brussels, BE)

19.10-19.40: Poster Session: 5’ for each poster, Discussant: Elisa Giovannetti (Amsterdam, NL) (6 posters) 19.45: Gala Dinner

Spiegelzaal, Paleis op de meir meir 50 2000 Antwerp

9

Thursday February 11th

8.30: Burger-Kelland PAMM Lecture Jacques Robert (Bordeaux, FR) Introduction Frits Peters 9.00: News from the Lab: Experimental Models Chair: A. Skladanowsky, Gdansk (PL)

09:00 - 09:20 PDX models, challenges and opportunities Iduna Fichtner (Berlin, DE)

09:20 - 09:40 Organoids Patrick Jacquemin (Brussels, BE)


09:50 - 10:20 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#5 Patient-derived lymphoma xenografts (PDX) in immune-deficient

nude mice and primary 3D cell cultures (PD3D) as pre-clinical toolboxes. B.

Brzezicha (Berlin, DE)

Abstract#18 Therapeutic response to chemotherapeutic drugs of glioma-PDX and correlation to common mutations identified by panel sequencing. A. Orthmann (Berlin, DE)


11.00: Minisymposium “Liquid Biopsies in Cancer”

Chair: Christian Rolfo (Antwerp, BE)

11:00 - 11:20 Circulating Tumor Cells Marta Castiglia (IT)

11:20 - 11:40 Circulating Free DNA Frederica Di Nicolantonio (Torino, IT)

11:40 - 12:00 Exosomes Riccardo Alessandro (Palermo, IT)

12:00 - 12:20 Platelets Myron Best (Amsterdam, NL)

12:20 – 12:30 NGS in liquid biopsies Lukas Heukamp (Köln, DE)


12:40 - 13:10 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#2 Comparison of exosome and exosomal RNA isolation methods in

NSCLC liquid biopsies. Assessment of hsa-miR-1228-3p as normalizer for

exosomal microRNA analysis. Marco Giallombardo (Palermo, IT)

Abstract#10 Circulating microRNAs as dynamic biomarkers of disease

progression during FOLFIRINOX therapy in unresectable pancreatic ductal

adenocarcinoma (PDAC). Laura Meijer (Amsterdam, NL)

13.10: Lunch and networking

10

14.00: Immuno checkpoints “the fashion topic…but really good enought?” Chairs: Antonio Russo (Palermo, IT)

14:00-14:20 Point of view of the Immunologist Evelien Smits (Antwerp, BE)

14:20-14:40 Point of view of Oncologist Antonio Araújo (Porto, PT)


14:50 - 15:25 Young investigators - 3 abstracts presentation: 3x10 = 30’ (and 5’ discussion : 2 questions) Abstract#11 Immune checkpoint expression and identification of immune

cells in human malignant pleural mesothelioma. Elly Marcq (Antwerp, BE)

Abstract#42 Cisplatin and anti-CD70 therapy: a promising combination

strategy for non-small cell lung cancer. Julie Jacobs (Antwerp, BE)


15.45: Assessment of your research with Molecular Imaging

Chair: Sigrid Stroobants (Antwerp, BE)

15:45 - 16:05 Preclinical research: Multimodality preclinical imaging Carla Molthoff (Amsterdam, NL)


16:15 - 16:45 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#4 Radiochemical synthesis of 18F ProTides for PET (Positron

Emission Tomography) Alessandra Cavaliere (Cardiff, UK)

Abstract#13 F-FDG-PET as an early response predictor in a HER-2

overexpressing breast cancer model treated with targeted PI3KAktmTOR

drugs Y. Dockx (Antwerp, BE)

16.45: Hot topics in short communications: Chair: Georg Hempel (Munster, DE)

16:45 - 17:05 Biotherapies: is PK the forgotten biomarker?Joseph Ciccolini (Marseille, FR)

17:05 - 17:25 New targets: deubiquitinases and mitochondrial disfunction Stig Linder (Stockholm, SE)

17:25 - 17:45 DNA Repair and synthetic lethality Rafael Rosell (Barcelona, ES)

17:45 - 18:05 Marine Alkaloids as Leads for Anticancer Drugs Patrizia Diana (Palermo, IT)


18:15 - 18:45 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#22 DDIT4 a promising marker in cancer. Williams Fajardo (Lima,

PE)

Abstract#40 Tolerability of FOLFOXIRI regimen after surgical resection for

pancreatic cancer: safety data and perspectives for ongoing adjuvant trials.

Chiara Caparello (Pisa, IT)

11

18.45 – 19.15: Poster Session: 5’ for each poster, Discussant: Andy Westwell (6 posters) 19.30: Walking city tour guided

12

Friday February 12th

8.30: Meet the expert: the importance of clinical trial design in drug development: the key of

success. Ignacio Gil Bazo (Pamplona, ES)

9.30: Resistance mechanisms in new drugs and how to overcome it Chair: Frits Peters (Amsterdam, NL)

09:30 - 09:50 Point of view of the Molecular Pathologist Patrick Pauwels (Antwerp, BE)

09:50 - 10:10 Point of view of the Pharmacologist Elisa Giovannetti (Amsterdam, NL)

10:10 - 10:30 Point of view of the Oncologist : clonal evolution and other mechanisms Ignacio Gil Bazo (Pamplona, ES)


10:40 - 11:10 Young investigators - 2 abstracts presentation: 2x10 = 20’ (and 5’ discussion : 2 questions) Abstract#26 Myristoylated alanine-rich C-kinase substrate (MARCKS)

facilitates exocytosis of polyubiquitinated proteins in bortezomib-resistant

leukemia cells as a novel modality for acquired resistance to proteasome

inhibitors. Jacqueline Cloos / Gerrit Jansen (Amsterdam, NL)

Abstract# 29 Flubendazole as potential anti-neuroblastoma therapy option.

Martin Michaelis (Canterbury, UK)

11.10: coffee break and poster visit

11.30: Minisymposium “Molecular Profiling in Cancer Patients” Chair: Monika Hegi (Zurich, SW)

Next Generation Sequencing: Commercial versus in house platforms:

11:30 - 11:45 Clinical research with NGS Luis Paz Ares (Madrid, Spain)

11:45 - 12:00 Point of view of industry Mark Kockx Histogenix (Antwerp, BE)

12:00 - 12:15 Point of view of Universities Aline Hébrant (Brussels, BE)

12:15 - 12:30 Molecular profiling in solid tumor: the example of metastatatic melanoma Fernando Vidal Vanaclocha (Madrid, ES)

Interpretation of data: the Oncologists dilemma.

12:30 - 12:45 Molecular Tumor Board Guiem Argiles (Barcelona, ES)

12:45 - 13:00 Tools for interpretation Istvan Petak (Budapest, HU)


13:10 - 13:40 Young investigators: 2 abstract presentation:2 x 10’ (and 5’ discussion: 2

questions)

Abstract#1 A prognostic signature based on 3-genes expression in triple

negative breast tumors with residual disease. J. A. Pinto Oblitas(Lima, PE)

Abstract#19 Ultra-deep targeted resequencing of 38 pancreatic neuroendocrine tumors reveals tumor heterogeneity for actionable mutations. Timon Vandamme (Antwerp, BE)

13

13.40 – 14:10: EORTC Business Meeting Session

14.10: Lunch and poster visit

14.40 – 15:10 Poster Session: 5’ for each poster, Discussant: Eric Raymond (6 posters) 15.10: PAMM meet others Chair: Denis Lacombe (Director-General, EORTC Brussels, BE)

15:10 - 15:25 Thoracic-oncology Group Benjamin Besse (Paris, FR)

15:25 - 15:40 Soft Tissue and Bone Sarcoma Group Alessandro Gronchi (Milan, IT)

15:40 - 16:00 ESMO Rolf Stahel (Zurich, CH)

16:00 - 16:15 Opening opportunities: Clinical Research in Latin America Joseph Arturo Pinto Oblitas(Lima, PE)

16.15: Coffee break and poster session

16.30: Hot topics in short communications: Clinical Trials Chair: Giuseppe Bronte (Palermo, IT)

16:30 - 16:45 Biostatistics applications in clinical research Urania Dafni (Athens, GR)

16:45 - 17:00 New regulatory in Europe for clinical Trials Anastasia Negrouk (EORTC Brussel, BE)

17:00 - 17:15 New fast track for drug approval: is only question of trial design? Anastasia Negrouk (EORTC Brussel, BE)


17.30: Young investigator PAMM 2016 best presentation and poster awards 18.30: PAMM 2017 Announcement – Closing Remarks from chairs.

scientific committee: local organization - … scientific committee: prof. dr. eric raymond prof....

Documents